Keyphrases
Clinical Trials
63%
Ramucirumab
59%
Risk Outcomes
59%
Patient Outcomes
59%
Risk-benefit
59%
Patient Benefit
59%
Drug Development
59%
Patient Risk
59%
Core Outcome Set
39%
Approved Indication
29%
Randomized Controlled Trial
27%
FDA-approved Drugs
22%
Clinical Trial Registry
20%
Reporting Guidelines
19%
Metabolism
19%
Diabetes
19%
Endocrinology
19%
Adverse Events
14%
Overall Survival
14%
Trialists
10%
Data Screening
9%
Screening Data
9%
Symptom Burden
8%
Efficacy Outcomes
7%
Oncology Drugs
7%
Positive Outcomes
7%
Medical Decision Making
7%
PubMed
7%
Evidence-based
7%
Excess Burden
7%
Off-label Indications
7%
Clinical Trial Failures
7%
Failure Rate
7%
Cochrane
7%
Embase
7%
Cancer Treatment
7%
MEDLINE
7%
Progression-free Survival
7%
Trial Participants
7%
Survival Benefit
7%
Gastric Cancer
7%
Poor Survival
7%
Literature Search
7%
Monotherapy
7%
Medicine and Dentistry
Clinical Trial
100%
Ramucirumab
59%
Randomized Controlled Trial
27%
Endocrinology
19%
Systematic Review
19%
Diabetes
19%
Student T Test
19%
Side Effect
14%
Adverse Event
14%
Overall Survival
14%
Clinician
11%
Drug Therapy
9%
Inferential Statistics
9%
Informed Consent
9%
Chi Square Test
9%
Human Subject
9%
Patient with Depression
9%
Awareness
9%
Medical Decision Making
7%
Malignant Neoplasm
7%
Cancer Therapy
7%
Progression Free Survival
7%
Monotherapy
7%
Abdominal Cancer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
74%
Drug Development
59%
Ramucirumab
59%
Randomized Controlled Trial
27%
Adverse Event
14%
Side Effect
14%
Overall Survival
14%
Malignant Neoplasm
14%
Progression Free Survival
7%
Abdominal Cancer
7%
Monotherapy
7%